Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 11/20 | 0.62 |
| ▸ | FNTB | P49356 | 11/20 | 0.62 |
| ▸ | HRAS | P01112 | 1/20 | 0.62 |
| ▸ | KRAS | P01116 | 1/20 | 0.62 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | GCKR | Q14397 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5755053 | 1.00 | FNTA (0.62) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL6614317 | 0.96 | FNTA (0.58) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL5754745 | 0.92 | FNTA (0.55) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL5787326 | 0.87 | FNTA (0.59) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL5787316 | 0.87 | FNTA (0.59) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL5757506 | 0.86 | FNTA (0.47) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL5757513 | 0.86 | FNTA (0.47) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL6615549 | 0.84 | FNTA (0.47) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL6630924 | 0.84 | FNTA (0.58) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL7666114 | 0.84 | FNTA (0.47) | FNTAFNTBHRASKRASPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074921-B2 | Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-07-11 | — | — | US | claimed |
| EP-1443936-A4 | PROCESS FOR THE PREPARATION OF 3,7-DISUBSTITUTED-2,3,4,5- TETRAHYDRO-1H-1,4-BENZODIAZEPINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2006-01-11 | — | — | EP | claimed |
| US-6949642-B2 | Production of tertiary amines by reductive amination | BRISTOL-MYERS SQUIBB CO. (US) | 2005-09-27 | — | — | US | claimed |
| EP-1443936-A2 | PROCESS FOR THE PREPARATION OF 3,7-DISUBSTITUTED-2,3,4,5- TETRAHYDRO-1H-1,4-BENZODIAZEPINE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2004-08-11 | — | — | EP | claimed |
| EP-1385832-A2 | PRODUCTION OF TERTIARY AMINES BY REDUCTIVE AMINATION | Bristol-Myers Squibb Company (US) | 2004-02-04 | — | — | EP | claimed |
| US-20030162965-A1 | Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-28 | — | — | US | claimed |
| WO-2003041658-A2 | PROCESS FOR THE PREPARATION OF 3,7-DISUBSTITUTED-2,3,4,5- TETRAHYDRO-1H-1,4-BENZODIAZEPINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-05-22 | — | — | WO | claimed |
| US-20020169313-A1 | Production of tertiary amines by reductive amination | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-14 | — | — | US | claimed |
| WO-2002085819-A2 | PRODUCTION OF TERTIARY AMINES BY REDUCTIVE AMINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-31 | — | — | WO | claimed |
| US-7074921-B2 | Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-07-11 | — | — | US | disclosed |
| EP-1443936-A4 | PROCESS FOR THE PREPARATION OF 3,7-DISUBSTITUTED-2,3,4,5- TETRAHYDRO-1H-1,4-BENZODIAZEPINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2006-01-11 | — | — | EP | disclosed |
| US-6949642-B2 | Production of tertiary amines by reductive amination | BRISTOL-MYERS SQUIBB CO. (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1481975-A1 | Inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| EP-1443936-A2 | PROCESS FOR THE PREPARATION OF 3,7-DISUBSTITUTED-2,3,4,5- TETRAHYDRO-1H-1,4-BENZODIAZEPINE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003041658-A2 | PROCESS FOR THE PREPARATION OF 3,7-DISUBSTITUTED-2,3,4,5- TETRAHYDRO-1H-1,4-BENZODIAZEPINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-05-22 | — | — | WO | disclosed |
| US-20020169313-A1 | Production of tertiary amines by reductive amination | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-14 | — | — | US | disclosed |
| WO-2002085819-A2 | PRODUCTION OF TERTIARY AMINES BY REDUCTIVE AMINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-31 | — | — | WO | disclosed |
| US-6458783-B1 | INHIBITION OF FARNESYL TRANSFERASE, WHICH IS AN ENZYME INVOLVED IN RAS ONCOGENE EXPRESSION, IS EFFECTED BY COMPOUNDS OF THE FORMULAS OF BENODIAZEPINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-01 | — | — | US | disclosed |
| US-6455523-B1 | ADMINISTERING 1,4-BENZODIAZEPINE DERIVATIVE AS ANTITUMOR OR ANTICARCINOGENIC AGENT | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-6011029-A | BENZODIAZEPINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169313-A1 | Production of tertiary amines by reductive amination | FNTB, ACAT2, SOAT2 | FNTA 7/4885FNTB 1/4885HRAS 2139/4885 |
| US-20030162965-A1 | Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds | GABRA4, GABRA3, GABRA6 | FNTA 43/4885FNTB 27/4885HRAS 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.